Octreotide Acetate
17 NDCs across 6 manufacturers|14 Generic,3 Brand
Octreotide Acetate is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms and pituitary neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 21, 1988, and the first generic was approved Mar 28, 2005. FDA's Orange Book lists 9 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $15 million on Octreotide Acetate across 16,000 claims for 3,596 beneficiaries.
Octreotide Acetate is available as 17 NDCs from 6 manufacturers (14 generic, 3 brand), with NADAC prices from $2.53 to $41.76 per ML — the most expensive product costs about 16× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
17
14G / 3B
Manufacturers
6
competing in market
Price Spread
$2.53 – $41.76
per ML, 14 of 17 NDCs
7d Activity
avg +5.2% WoW · of 17 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Fresenius Kabi USA, LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Somatostatin Analog class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing OCTREOTIDE ACETATE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SANDOSTATIN LAR DEPOT 30 MG KT | $6948.0840 per EA | — |
SANDOSTATIN LAR DEPOT 20 MG KT | $4588.5469 per EA | — |
SANDOSTATIN LAR DEPOT 10 MG KT | $3523.0291 per EA | — |
OCTREOTIDE 1,000 MCG/ML VIAL | $41.7580 per ML | — |
OCTREOTIDE 1,000 MCG/5 ML VIAL | $5.3404 per ML | — |
OCTREOTIDE 1,000 MCG/5 ML VIAL | $5.3404 per ML | — |
OCTREOTIDE 1,000 MCG/5 ML VIAL | $5.3404 per ML | — |
OCTREOTIDE 1,000 MCG/5 ML VIAL | $5.3404 per ML | — |
OCTREOTIDE ACET 50 MCG/ML VIAL | $2.6422 per ML | — |
OCTREOTIDE ACET 50 MCG/ML VIAL | $2.6422 per ML | — |
OCTREOTIDE ACET 50 MCG/ML VIAL | $2.6422 per ML | — |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
OCTREOTIDE ACET 100 MCG/ML VL | $2.5346 per ML | +5.18% |
Frequently Asked Questions
What is Octreotide Acetate used to treat?
Octreotide Acetate is used to treat acromegaly, adenoma, diarrhea, pancreatic neoplasms and pituitary neoplasms, per the National Library of Medicine's MED-RT classification.
When did Octreotide Acetate become available as a generic?
FDA approved the first generic Octreotide Acetate (ANDA) on Mar 28, 2005. The Orange Book currently lists 9 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Octreotide Acetate?
In 2024, Medicare Part D spent $15 million on Octreotide Acetate across 16,000 claims for 3,596 beneficiaries.
How many Octreotide Acetate products are on the market?
The Octreotide Acetate drug market contains 17 NDCs from 6 manufacturers — 14 generic and 3 brand products.
What is the price range for Octreotide Acetate?
NADAC reference prices for Octreotide Acetate range from $2.5346 to $41.7580 per ML — the most expensive product costs about 16× the cheapest. 3 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Which manufacturers make Octreotide Acetate?
6 manufacturers list Octreotide Acetate in NADAC. Ranked by number of NDCs, the largest are Fresenius Kabi USA, LLC (4), Novartis Pharmaceuticals Corporation (3), Hikma Pharmaceuticals USA Inc. (3), Sagent Pharmaceuticals (3), Heritage Pharmaceuticals Inc. (3).
How has the price of Octreotide Acetate changed recently?
Over the past 7 days, 6 Octreotide Acetate NDCs rose and 0 fell, with a market-wide average change of +5.2%.